IL122976A0 - Control of cd44 gene expression for therapeutic use - Google Patents

Control of cd44 gene expression for therapeutic use

Info

Publication number
IL122976A0
IL122976A0 IL12297696A IL12297696A IL122976A0 IL 122976 A0 IL122976 A0 IL 122976A0 IL 12297696 A IL12297696 A IL 12297696A IL 12297696 A IL12297696 A IL 12297696A IL 122976 A0 IL122976 A0 IL 122976A0
Authority
IL
Israel
Prior art keywords
control
gene expression
therapeutic use
therapeutic
gene
Prior art date
Application number
IL12297696A
Other languages
English (en)
Original Assignee
Icn Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icn Pharmaceuticals filed Critical Icn Pharmaceuticals
Publication of IL122976A0 publication Critical patent/IL122976A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL12297696A 1995-08-14 1996-07-31 Control of cd44 gene expression for therapeutic use IL122976A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/514,542 US5990299A (en) 1995-08-14 1995-08-14 Control of CD44 gene expression for therapeutic use
PCT/US1996/012598 WO1997006827A1 (en) 1995-08-14 1996-07-31 Control of cd44 gene expression for therapeutic use

Publications (1)

Publication Number Publication Date
IL122976A0 true IL122976A0 (en) 1998-08-16

Family

ID=24047640

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12297696A IL122976A0 (en) 1995-08-14 1996-07-31 Control of cd44 gene expression for therapeutic use

Country Status (13)

Country Link
US (1) US5990299A (sk)
EP (1) EP0846001A4 (sk)
JP (1) JPH11505129A (sk)
KR (1) KR19990036277A (sk)
CN (1) CN1193280A (sk)
AU (1) AU704579B2 (sk)
CA (1) CA2228965A1 (sk)
CZ (1) CZ43898A3 (sk)
IL (1) IL122976A0 (sk)
MX (1) MX9801264A (sk)
PL (1) PL327628A1 (sk)
SK (1) SK18598A3 (sk)
WO (1) WO1997006827A1 (sk)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262249B1 (en) * 1998-06-23 2001-07-17 Chiron Corporation Pancreatic cancer genes
US6150162A (en) * 1998-12-17 2000-11-21 Isis Pharmaceuticals Inc. Antisense modulation of CD44 expression
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
HUP0300627A3 (en) * 1999-12-13 2005-11-28 Bioniche Life Sciences Inc Bel Therapeutically useful synthetic oligonucleotides
CA2426047A1 (en) * 2000-11-02 2002-05-10 Inex Pharmaceuticals Corporation Therapeutic oligonucleotides of reduced toxicity
WO2003006478A1 (en) * 2001-07-10 2003-01-23 Oligos Etc. Inc. Oligonucleotide-containing pharmacological compositions and their use
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US7829277B2 (en) * 2004-03-01 2010-11-09 The Regents Of The University Of California Methods for identifying compounds that suppress chemically-induced carcinogenesis
WO2006103442A2 (en) * 2005-04-01 2006-10-05 Ncc Technology Ventures Pte. Ltd. Materials and methods relating to breast cancer classification
US7932032B2 (en) * 2005-05-02 2011-04-26 Toray Industries, Inc. Method for diagnosing esophageal cancer
EP1893776A2 (en) * 2005-06-03 2008-03-05 Aviaradx, Inc. Normalization genes
WO2007038792A2 (en) * 2005-09-28 2007-04-05 H. Lee Moffitt Cancer Center Individualized cancer treatments
DE102005052384B4 (de) * 2005-10-31 2009-09-24 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Erkennung, Markierung und Behandlung von epithelialen Lungentumorzellen sowie Mittel zur Durchführung des Verfahrens
KR20100044793A (ko) 2007-07-10 2010-04-30 뉴림 파머슈티칼스 (1991) 리미티드 신경퇴행성 질환에서 ｃｄ44 접목 변이체들
EP2060583A1 (en) * 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
WO2009142257A1 (ja) * 2008-05-21 2009-11-26 東レ株式会社 食道ガン判定用組成物及び方法
EP2444503B1 (en) * 2010-10-20 2016-03-02 Université Joseph Fourier Use of specific genes for the prognosis of lung cancer and the corresponding progonosis method
JP6017448B2 (ja) * 2010-12-22 2016-11-02 ユニヴェルシテ フランソワ ラブレー ドゥ トゥールＵｎｉｖｅｒｓｉｔｅ Ｆｒａｎｃｏｉｓ Ｒａｂｅｌａｉｓ Ｄｅ Ｔｏｕｒｓ 血液疾患の診断方法
KR20140049984A (ko) * 2011-04-25 2014-04-28 도레이 카부시키가이샤 유방암 환자의 트라스투주마브에 대한 치료 감수성 예측용 조성물 및 방법
US20140329230A1 (en) * 2011-11-15 2014-11-06 University Of Miami Methods for detecting human papillomavirus and providing prognosis for head and neck squamous cell carcinoma
US9938583B2 (en) 2013-03-15 2018-04-10 Varian Medical Systems, Inc. Biomarkers for radiation treatment
WO2015176067A2 (en) * 2014-05-16 2015-11-19 The Regents Of The University Of California A long non-coding rna expressed in aggressive cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT98326B (pt) * 1990-07-13 1999-01-29 Gen Hospital Corp Processos para a preparacao de antigenios de superficie celular, cd27, cd53 e tlisa, e de composicoes farmaceuticas compreendendo os referidos antigenios
JPH09508265A (ja) * 1994-01-18 1997-08-26 プレジデント アンド フェロウズ オブ ハーバード カレッジ 平滑筋細胞におけるｃｄ４４発現

Also Published As

Publication number Publication date
CZ43898A3 (cs) 1998-07-15
PL327628A1 (en) 1998-12-21
CN1193280A (zh) 1998-09-16
MX9801264A (es) 1998-11-29
EP0846001A1 (en) 1998-06-10
SK18598A3 (en) 1998-07-08
US5990299A (en) 1999-11-23
KR19990036277A (ko) 1999-05-25
CA2228965A1 (en) 1997-02-27
EP0846001A4 (en) 1999-10-20
AU6686696A (en) 1997-03-12
WO1997006827A1 (en) 1997-02-27
JPH11505129A (ja) 1999-05-18
AU704579B2 (en) 1999-04-29

Similar Documents

Publication Publication Date Title
IL122976A0 (en) Control of cd44 gene expression for therapeutic use
ZA961587B (en) Gene transfer-mediated angiogenesis therapy
HK1008979A1 (en) Gene transfer-mediated angiogenesis therapy
ZA956410B (en) Control of plant gene expression
AU7353494A (en) Episomal expression vector for human gene therapy
EP0814846A4 (en) GENE THERAPY BY EXPRESSION OF SECRECTIVE GLANDS
EP0789592A4 (en) GENE EYE THERAPY
AU5178296A (en) Induction of e-selectin for targetting therapeutic agents
AU3972893A (en) Gene therapy using the intestine
GB9514437D0 (en) Inhibition of gene expression
GB9514435D0 (en) Inhibition of gene expression
LT2000039A (en) Biocontrol agents for control of root diseases
IL117713A0 (en) Gene expression system
AU7310896A (en) Use of nitroflavonoids for the treatment of anxiety
HUP9900750A3 (en) Promoters for gene expression
GB9506051D0 (en) Gene expression
AU4941096A (en) Self-deleting vectors for gene therapy
AU5010196A (en) Therapeutic benzoxazoles
HUP9902834A3 (en) Control of cd44 gene expression for therapeutic use
GB9524942D0 (en) Drug therapy
AU6171196A (en) Therapeutic uses of ta99
AU1370397A (en) Process for the purification of recombinant human interleukin-8
AU7944498A (en) System for applying a therapeutic action to the organism of a patient
GB9510223D0 (en) Therapeutic agent
GB9520433D0 (en) Gene therapy